- Home
- ATNF vs RNAZ Comparison
ATNF vs RNAZ Comparison
Compare ATNF & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNF
- RNAZ
- Stock Information
- Founded
- ATNF 2016
- RNAZ 2016
- Country
- ATNF United States
- RNAZ United States
- Employees
- ATNF N/A
- RNAZ N/A
- Industry
- ATNF Biotechnology: Pharmaceutical Preparations
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- ATNF Health Care
- RNAZ Health Care
- Exchange
- ATNF Nasdaq
- RNAZ Nasdaq
- Market Cap
- ATNF 5.7M
- RNAZ 4.9M
- IPO Year
- ATNF N/A
- RNAZ 2021
- Fundamental
- Price
- ATNF $1.46
- RNAZ $3.50
- Analyst Decision
- ATNF
- RNAZ Strong Buy
- Analyst Count
- ATNF 0
- RNAZ 1
- Target Price
- ATNF N/A
- RNAZ $20.00
- AVG Volume (30 Days)
- ATNF 1.1M
- RNAZ 102.5K
- Earning Date
- ATNF 02-13-2025
- RNAZ 11-14-2024
- Dividend Yield
- ATNF N/A
- RNAZ N/A
- EPS Growth
- ATNF N/A
- RNAZ N/A
- EPS
- ATNF N/A
- RNAZ N/A
- Revenue
- ATNF N/A
- RNAZ N/A
- Revenue This Year
- ATNF N/A
- RNAZ N/A
- Revenue Next Year
- ATNF $54.15
- RNAZ N/A
- P/E Ratio
- ATNF N/A
- RNAZ N/A
- Revenue Growth
- ATNF N/A
- RNAZ N/A
- 52 Week Low
- ATNF $1.16
- RNAZ $2.66
- 52 Week High
- ATNF $17.75
- RNAZ $66.33
- Technical
- Relative Strength Index (RSI)
- ATNF 39.69
- RNAZ 31.97
- Support Level
- ATNF $1.43
- RNAZ $2.90
- Resistance Level
- ATNF $1.67
- RNAZ $3.61
- Average True Range (ATR)
- ATNF 0.13
- RNAZ 0.35
- MACD
- ATNF 0.00
- RNAZ 0.32
- Stochastic Oscillator
- ATNF 21.82
- RNAZ 53.68
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.